RxDoctor Payments Data

Bruce Galonsky, MD

Family Medicine · Battle Creek, MINPI 1003996547

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Ascensia Diabetes Care US Inc. at 32.7% of the total. 2025 is the largest year on record at $155, 4.7 times the $33 reported in 2020. That places this record below the midpoint for family medicine clinicians in MI, where the typical reported total is $260.

$338in general payments, 2019–2025

Across 12 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascensia Diabetes Care US Inc.$110
  • Novo Nordisk$98
  • Amgen$71
  • GSK$33
  • Abbott$24

What the payments were for

  • Food & beverage$338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ascensia Diabetes Care US Inc.3$110
Novo Nordisk5$98
Amgen1$71
GSK2$33
Abbott1$24

How this compares

$338 in reported general payments places this provider in the 50th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$145,263
Medicare patients
559
Services billed
3,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$76,453
TrulicityDulaglutide37$51,876
JardianceEmpagliflozin26$43,861
OzempicSemaglutide23$41,668
ArexvyRsvpref3 Antigen/As01e/Pf125$39,020
ShingrixVaricella-Zoster Ge/As01b/Pf148$33,138
MounjaroTirzepatide18$17,581
Tresiba Flextouch U-100Insulin Degludec14$15,675
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$6,447
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf86$6,293
Atorvastatin Calcium324$4,628
Rosuvastatin Calcium235$4,461
Tamsulosin Hcl108$2,801
Gabapentin103$2,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Trelegy Ellipta$33$85,026288 claims
Novo NordiskOzempic$98$41,66823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →